Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects

References

• Wolf G. A history of vitamin A and retinoids. FASEB J. 1996;10:1102–7.
   PubMedGoogle Scholar
• Harrison EH. Mechanisms involved in the intestinal absorption of dietary vitamin A and provitamin A carotenoids. Biochim Biophys Acta. 2012;1821:70–7.
   PubMed Web of Science ®Google Scholar
• Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J. 2000;348:481–95.
   PubMed Web of Science ®Google Scholar
• Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010;62:1285–98.
   PubMed Web of Science ®Google Scholar
• Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004;328:1–16.
   PubMed Web of Science ®Google Scholar
• Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol. 2006;66:606–30.
   PubMedGoogle Scholar
• Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1:327–48.
   PubMed Web of Science ®Google Scholar
• Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol. 1998;39:S25–S33.
   PubMed Web of Science ®Google Scholar
• Briggs GFR, Yaffe S. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th edition. Philadelphia (PA): Lippincott Williams & Wilkins; 2012. p. 16–18.
   Google Scholar
• Andersson E, Rosdahl I, Torma H, Vahlquist A. Differential effects of UV irradiation on nuclear retinoid receptor levels in cultured keratinocytes and melanocytes. Exp Dermatol. 2003;12:563–71.
   PubMed Web of Science ®Google Scholar
• Moy A, McNamara NA, Lin MC. Effects of isotretinoin on meibomian glands. Optom Vis Sci. 2015;92:925–30.
   PubMed Web of Science ®Google Scholar
• Saurat JH. Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol. 1992;27:S23–S8.
   PubMed Web of Science ®Google Scholar
• Henning P, Conaway HH, Lerner UH. Retinoid receptors in bone and their role in bone remodeling. Front Endocrinol. 2015;6:31.
   PubMed Web of Science ®Google Scholar
• Golczak M, Maeda A, Bereta G, et al. Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina. J Biol Chem. 2008;283:9543–54.
   PubMed Web of Science ®Google Scholar
• Sorg O, Kuenzli S, Saurat JH. Side effects and pitfalls in retinoid therapy. In: Vahlquist A, Duvic M, eds. Retinoids and Carotenoids in Dermatology. Vol. 39; 2007. p. 225–48.
   Google Scholar
• Lee YH, Scharnitz TP, Muscat J, et al. Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:35–44.
   PubMed Web of Science ®Google Scholar
• Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology (Basel). 2002;204:232–5.
   PubMed Web of Science ®Google Scholar
• Seitz HK. Alcohol and retinoid metabolism. Gut. 2000;47:748–50.
   PubMed Web of Science ®Google Scholar
• Cunningham FG. Williams Obstetrics, 24 ed. New York: McGraw-Hill Education; 2014.
   Google Scholar
• Chen C, Jensen BK, Mistry G, et al. Negligible systemic absorption of topical isotretinoin cream: implications for teratogenicity. J Clin Pharmacol. 1997;37:279–84.
   PubMed Web of Science ®Google Scholar
• Nohynek GJ, Meuling WJ, Vaes WH, et al. Repeated topical treatment, in contrast to single oral doses, with vitamin A-containing preparations does not affect plasma concentrations of retinol, retinyl esters or retinoic acids in female subjects of child-bearing age. Toxicol Lett. 2006;163:65–76.
   PubMed Web of Science ®Google Scholar
• Yu Z, Sefton J, Lew-Kaya D, et al. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. Clin Pharm. 2003;42:921–9.
   Google Scholar
• Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry. 2012;73:37–50.
   PubMed Web of Science ®Google Scholar
• Ludot M, Mouchabac S, Ferreri F. Inter-relationships between isotretinoin treatment and psychiatric disorders: depression, bipolar disorder, anxiety, psychosis and suicide risks. World J Psychiatry. 2015;5:222–7.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Cunliffe W, Berson D, Global Alliance to Improve Outcomes in A, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1–S37.
   PubMed Web of Science ®Google Scholar
• Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139:8–11.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002;69:12–9.
   PubMedGoogle Scholar
• Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67:4–9.
   PubMedGoogle Scholar
• Cunliffe WJ, Danby FW, Dunlap F, et al. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol: EJD. 2002;12:350–4.
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68:10–9.
   PubMedGoogle Scholar
• Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis. 2001;67:10–6.
   PubMedGoogle Scholar
• Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7:S3–S10.
   PubMed Web of Science ®Google Scholar
• Pariser D, Colon LE, Johnson LA, Gottschalk RW. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7:S18–S23.
   PubMed Web of Science ®Google Scholar
• Shalita AMB, Menter A, Abramovits W, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2004;4:153–8.
   Google Scholar
• Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69:4–11.
   PubMedGoogle Scholar
• Kunynetz RA. A review of systemic retinoid therapy for acne and related conditions. Skin Ther Lett. 2004;9:1–4.
   PubMedGoogle Scholar
• Layton A. The use of isotretinoin in acne. Dermato-Endocrinol. 2009;1:162–9.
   PubMedGoogle Scholar
• Agarwal US, Besarwal RK, Bhola K. Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial. Indian J Dermatol Venereol Leprol. 2011;77:688–94.
   PubMed Web of Science ®Google Scholar
• Boyraz N, Mustak PK. Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimens in the treatment of moderate acne vulgaris. Int J Dermatol. 2013;52:1265–7.
   PubMed Web of Science ®Google Scholar
• Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:644–6.
   PubMed Web of Science ®Google Scholar
• Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013;149:1392–8.
   PubMed Web of Science ®Google Scholar
• Altinyazar HC, Koca R, Tekin NS, Esturk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol. 2005;44:252–5.
   PubMed Web of Science ®Google Scholar
• Chang AL, Alora-Palli M, Lima XT, et al. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. J Drugs Dermatol. 2012;11:333–9.
   PubMed Web of Science ®Google Scholar
• Abokwidir MFS. Rosacea management. Skin Appendage Disord. 2016;2:26–34.
   PubMed Web of Science ®Google Scholar
• Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesth Dermatol. 2011;4:54–61.
   Google Scholar
• Blok JL, van Hattem S, Jonkman MF, Horvath B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243–52.
   PubMed Web of Science ®Google Scholar
• Jansen I, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol. 2001;15:532–40.
   PubMed Web of Science ®Google Scholar
• Carretero GRM, Belinchón I, Carrascosa J, et al. Acitretina: guía de uso en psoriasis. Actas Dermo-Sifiliograficas. 2013;104:598–616.
   PubMedGoogle Scholar
• Blair HA, Scott LJ. Alitretinoin: a review in severe chronic hand eczema. Drugs. 2016;76:1271–9.
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760–7.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38:705–11.
   PubMed Web of Science ®Google Scholar
• Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high-or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002;6:95–102.
   PubMed Web of Science ®Google Scholar
• Behrens S, Grundmann-Kollmann M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol. 2000;42:493–5.
   PubMed Web of Science ®Google Scholar
• Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol. 2000;43:821–8.
   PubMed Web of Science ®Google Scholar
• Kaur I, Dogra S, Jain R, Kumar B. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian J Dermatol Venereol Leprol. 2008;74:471–4.
   PubMed Web of Science ®Google Scholar
• Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: an observer-blinded randomized controlled study. Indian J Dermatol. 2011;56:40–3.
   PubMedGoogle Scholar
• Sarkar R, Chugh S, Garg VK. Acitretin in dermatology. Indian J Dermatol Venereol Leprol. 2013;79:759–71.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica. 1988;177:218–24.
   PubMedGoogle Scholar
• Sommerburg C. Acitretin in combination with PUVA: a randomized double-blind placebo-controlled study in severe psoriasis. J Eur Acad Dermatol Venereol. 1993;2:308–17.
   Google Scholar
• Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145:269–71.
   PubMedGoogle Scholar
• Caldarola G, Zampetti A, De Simone C, et al. Circumscribed pityriasis rubra pilaris type IV. Clin Exp Dermatol. 2007;32:471–2.
   PubMed Web of Science ®Google Scholar
• Arnold AW, Buechner SA. Circumscribed juvenile pityriasis rubra pilaris. J Eur Acad Dermatol Venereol. 2004;18:705–7.
   PubMed Web of Science ®Google Scholar
• Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31:997–9.
   PubMed Web of Science ®Google Scholar
• Petruzzi M, Lucchese A, Lajolo C, et al. Topical retinoids in oral lichen planus treatment: an overview. Dermatology (Basel). 2013;226:61–7.
   PubMed Web of Science ®Google Scholar
• Wolff M, Sabzevari N, Gropper C, Hoffman C. A case of lichen planus pigmentosus with facial dyspigmentation responsive to combination therapy with chemical peels and topical retinoids. J Clin Aesthet Dermatol. 2016;9:44–50.
   PubMedGoogle Scholar
• Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol. 1991;24:434–7.
   PubMed Web of Science ®Google Scholar
• Solak B, Kara RO, Kosem M. Palmoplantar lichen planus successfully treated with acitretin. BMJ Case Rep. 2015;2015:bcr2015211115.
   Google Scholar
• Alsenaid A, Eder I, Ruzicka T, et al. Successful treatment of nail lichen planus with alitretinoin: report of 2 cases and review of the literature. Dermatology. 2014;229:293–6.
   PubMed Web of Science ®Google Scholar
• Kolios AG, Marques Maggio E, Gubler C, et al. Oral, esophageal and cutaneous lichen ruber planus controlled with alitretinoin: case report and review of the literature. Dermatology (Basel). 2013;226:302–10.
   PubMed Web of Science ®Google Scholar
• Kunz M, Urosevic-Maiwald M, Goldinger SM, et al. Efficacy and safety of oral alitretinoin in severe oral lichen planus–results of a prospective pilot study. J Eur Acad Dermatol Venereol. 2016;30:293–8.
   PubMed Web of Science ®Google Scholar
• Digiovanna JJ, Mauro T, Milstone LM, et al. Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther. 2013;26:26–38.
   PubMed Web of Science ®Google Scholar
• Fritsch P, Honigsmann H, Jaschke E. Epidermolytic hereditary palmoplantar keratoderma. Report of a family and treatment with an oral aromatic retinoid. Brit J Dermatol. 1978;99:561–8.
   PubMed Web of Science ®Google Scholar
• Cooper SM, Burge SM. Darier's disease: epidemiology, pathophysiology, and management. Am J Clin Dermatol. 2003;4:97–105.
   PubMed Web of Science ®Google Scholar
• Dogan S, Karaduman A, Erkin G, Gokoz O. Effective treatment of linear Darier's disease with topical retinoids: case report and review of the literature. Acta Dermatovenerol Croat. 2011;19:206–9.
   PubMed Web of Science ®Google Scholar
• Burge SM, Wilkinson JD, Miller AJ, Ryan TJ. The efficacy of an aromatic retinoid, Tigason (etretinate), in the treatment of Darier's disease. Br J Dermatol. 1981;104:675–9.
   PubMed Web of Science ®Google Scholar
• van Dooren-Greebe RJ, van de Kerkhof PC, Happle R. Acitretin monotherapy in Darier's disease. Br J Dermatol. 1989;121:375–9.
   PubMed Web of Science ®Google Scholar
• Dicken CH, Bauer EA, Hazen PG, et al. Isotretinoin treatment of Darier's disease. J Am Acad Dermatol. 1982;6:721–6.
   PubMed Web of Science ®Google Scholar
• Anuset D, Goutorbe C, Bernard P, Reguiai Z. Efficacy of oral alitretinoin for the treatment of Darier disease: a case report. J Am Acad Dermatol. 2014;71:e46–8.
   PubMed Web of Science ®Google Scholar
• Letule V, Herzinger T, Ruzicka T, Molin S. Treatment of Darier disease with oral alitretinoin. Clin Exp Dermatol. 2013;38:523–5.
   PubMed Web of Science ®Google Scholar
• Samuel M, Brooke RC, Hollis S, Griffiths CE. Interventions for photodamaged skin. Cochrane Database Syst Rev. 2005;CD001782.
   PubMed Web of Science ®Google Scholar
• Rabello-Fonseca RM, Azulay DR, Luiz RR, et al. Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication. J Eur Acad Dermatol Venereol. 2009;23:115–23.
   PubMed Web of Science ®Google Scholar
• Bagatin E, Guadanhim LR, Enokihara MM, et al. Low-dose oral isotretinoin versus topical retinoic acid for photoaging: a randomized, comparative study. Int J Dermatol. 2014;53:114–22.
   PubMed Web of Science ®Google Scholar
• Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000;16:1084–9.
   PubMed Web of Science ®Google Scholar
• Ianhez M, Fleury LF Jr, Miot HA, Bagatin E. Retinoids for prevention and treatment of actinic keratosis. Anais Brasil Dermatol. 2013;88:585–93.
   PubMed Web of Science ®Google Scholar
• Weinstock MA, Bingham SF, Digiovanna JJ, Veterans Affairs Topical Tretinoin Chemoprevention Trial G, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132:1583–90.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Meyskens FL Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med. 1987;107:499–502.
   PubMed Web of Science ®Google Scholar
• Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003;49:644–50.
   PubMed Web of Science ®Google Scholar
• Anforth R, Blumetti TC, Clements A, et al. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013;169:1310–3.
   PubMed Web of Science ®Google Scholar
• Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–56.
   PubMed Web of Science ®Google Scholar
• Peck GL, Gross EG, Butkus D, DiGiovanna JJ. Chemoprevention of basal cell carcinoma with isotretinoin. J Am Acad Dermatol. 1982;6:815–23.
   PubMed Web of Science ®Google Scholar
• Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992;84:328–32.
   PubMedGoogle Scholar
• Carneiro RV, Sotto MN, Azevedo LS, et al. Acitretin and skin cancer in kidney transplanted patients. Clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans' cells in sun exposed and sun protected skin. Clin Transplant. 2005;19:115–21.
   PubMed Web of Science ®Google Scholar
• De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg: Off Publication for Am Soc Dermatol Surg [Et Al]. 2004;30:656–61.
   PubMed Web of Science ®Google Scholar
• Heald P, Mehlmauer M, Martin AG, Worldwide Bexarotene Study G, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49:801–15.
   PubMed Web of Science ®Google Scholar
• Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol. 2009;160:1299–307.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol. 2004;51:25–32.
   PubMed Web of Science ®Google Scholar
• Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011;103:1572–87.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168:192–200.
   PubMed Web of Science ®Google Scholar
• Tousi B. The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence. Neuropsychiatr Dis Treat. 2015;11:311–5.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr. 1999;22:235–46.
   PubMed Web of Science ®Google Scholar
• Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir–Torre syndrome. J Am Acad Dermatol. 1985;12:475–80.
   PubMed Web of Science ®Google Scholar
• Marcusson JA, Bjarnason B, Ros AM. Isotretinoin for sebaceous skin lesions in Muir-Torre syndrome: a case report. Acta Derm Venereol. 1998;78:479–80.
   Google Scholar
• Graefe T, Wollina U, Schulz H, Burgdorf W. Muir–Torre syndrome – treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology. 2000;200:331–3.
   PubMed Web of Science ®Google Scholar